Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/9/2024 | $11.00 | Buy | Craig Hallum |
| 8/28/2024 | $12.00 | Outperform | Oppenheimer |
| 11/5/2021 | $17.00 | Buy | Chardan Capital Markets |
| 11/2/2021 | $23.00 | Outperform | Robert W. Baird |
| 11/2/2021 | $23.00 | Outperform | Baird |
4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
Sioux Falls, SD , March 29, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results March 29, 2024 SAB-142 Phase 1 trial on track for data release during 2024 Completed financing for up to $110 million with leading life science investors Cash and equivalents of $56.6 million as of December 31, 2023 Company expects its cash and equivalents, with exercise of Tranche B warrants, will fund operations into 2026 Sioux Falls, SD March 29, 2024 (GlobeNewswire)—SAB Biotherapeutics, Inc. (NASDAQ:SABS), ("SAB" or "the company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immun
10-Q - SAB Biotherapeutics, Inc. (0001833214) (Filer)
8-K - SAB Biotherapeutics, Inc. (0001833214) (Filer)
S-8 - SAB Biotherapeutics, Inc. (0001833214) (Filer)
SC 13G/A - SAB Biotherapeutics, Inc. (0001833214) (Subject)
SC 13G - SAB Biotherapeutics, Inc. (0001833214) (Subject)
SC 13G/A - SAB Biotherapeutics, Inc. (0001833214) (Subject)
Craig Hallum initiated coverage of SAB BIO with a rating of Buy and set a new price target of $11.00
Oppenheimer initiated coverage of SAB BIO with a rating of Outperform and set a new price target of $12.00
Chardan Capital Markets initiated coverage of SAB Biotherapeutics with a rating of Buy and set a new price target of $17.00
Company announced completed Phase 1 enrollment for SAB-142 with no observation of serum sickness. The company remains on track for a topline Phase 1 data readout by the end of the year. MIAMI, Nov. 06, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today reported financial results for the second quarter ended September 30, 2024, and provided a company update. "This quarter we were pleased to report completed enrollment of SAB-142 Phase 1 study with no
MIAMI, Oct. 31, 2024 (GLOBE NEWSWIRE) -- SAB BIO (NASDAQ:SABS) (the "Company" or "SAB"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that Chairman and CEO Samuel J. Reich will be speaking at an upcoming fireside chat at the 2024 Guggenheim Securities Healthcare Innovation Conference held November 11th – 13th, 2024 in Boston, MA. Event Details: Monday, November 11, 2024 at 3:00pm EST Location: Boston, MAWebcast Registration Link: https://wsw.com/webcast/guggen/sabs/1934789 A recording of the webcast will be accessible th
MIAMI, Sept. 13, 2024 (GLOBE NEWSWIRE) -- SAB BIO (NASDAQ:SABS) (the "Company" or "SAB"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of T1D, today announced that Chairman and CEO Samuel J. Reich will be participating in a fireside chat at the 2024 Cantor Global Healthcare Conference, September 17-19th, 2024. Fireside Chat: September 18th, 2024, at 8:00 am ETLocation: New York, NYWebcast Registration Link: Here A recording of the webcast will be accessible through the "Events" section of the Company's website at https://ir.sab.bio/news-events/events. About SAB
Gainers Tempest Therapeutics (NASDAQ:TPST) shares rose 32.8% to $3.79 during Thursday's pre-market session. The company's market cap stands at $84.0 million. Neurogene (NASDAQ:NGNE) shares rose 31.92% to $40.0. The company's market cap stands at $519.2 million. Geovax Labs (NASDAQ:GOVX) shares rose 28.94% to $2.45. The company's market cap stands at $6.1 million. SAB Biotherapeutics (NASDAQ:SABS) stock moved upwards by 24.03% to $3.2. The market value of their outstanding shares is at $29.5 million. Trevena (NASDAQ:TRVN) stock rose 23.33% to $0.44. The market value of their outstanding shares is at $8.0 million. Molecular Partners (NASDAQ:MOLN) stock rose 22.23% to $9.73. The company's
SAB Biotherapeutics (NASDAQ:SABS) (the "Company" or "SAB"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced its new name, SAB BIO, and visual identity to more closely align with its mission to treat and prevent immune and autoimmune disorders with the use of its unique immunotherapy platform. This rebrand includes a new name, logo mark and website updates to reflect the company's strategic evolution. "Our business has transformed significantly in the past year, with our singular focus on developing therapies that have the pote
Gainers Nexalin Technology (NASDAQ:NXL) stock increased by 48.1% to $1.54 during Wednesday's after-market session. The company's market cap stands at $11.4 million. Tempest Therapeutics (NASDAQ:TPST) stock moved upwards by 40.0% to $3.99. The market value of their outstanding shares is at $88.6 million. ASLAN Pharma (NASDAQ:ASLN) stock increased by 18.51% to $0.37. The market value of their outstanding shares is at $8.3 million. Talphera (NASDAQ:TLPH) shares increased by 15.18% to $0.9. The company's market cap stands at $15.2 million. Geovax Labs (NASDAQ:GOVX) stock rose 13.15% to $2.15. The market value of their outstanding shares is at $5.4 million. SAB Biotherapeutics (NASDAQ:SABS)
4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
3 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
FDA provided clearance to SAB's IND Appointed Lucy To as Chief Financial Officer Announced founding of a new Clinical Advisory Board MIAMI, Aug. 08, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today reported financial results for the second quarter ended June 30, 2024, and provided a company update. "We've had a strong quarter as we drive closer to our upcoming SAB-142 milestones. We continue to see an urgent need for transformative therapies in this spa
MIAMI, July 31, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that Lucy To has been named Chief Financial Officer effective August 12, 2024. Ms. To brings over 18 years of investment banking and strategic operational expertise to SAB and will lead corporate finance, corporate strategy and approach to broader strategic business relationships at the company. "Lucy's proven track record and experience will prove invaluable t
MIAMI, May 20, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today reported financial results for the first quarter ended March 31, 2024, and provided a company update. "As we work towards upcoming SAB-142 milestones, I remain enthusiastic about our ongoing progress executing a focused corporate strategy centered on immunotherapy, T1D," notes SAB chairman and CEO Samuel J. Reich, "Additionally, our recent appointment of Dr. Skyler to our Boa